These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 2041555)

  • 21. [Production of interleukin-1 and interleukin-6 in a culture of mononuclear cells of peripheral blood and bone marrow in multiple myeloma].
    Kliushnenkova EN; Lutskaia TD; Golenkov AK; Malaĭtsev VV
    Biull Eksp Biol Med; 1993 May; 115(5):507-10. PubMed ID: 8043836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Norepinephrine producing renal cell carcinoma.
    Koh CJ; Bochner BH; Stein JP; Fedenko AN; Dequattro V; Skinner DG
    J Urol; 2001 Aug; 166(2):603. PubMed ID: 11458078
    [No Abstract]   [Full Text] [Related]  

  • 23. [Studies on the interaction between interleukin-6 and human renal cell carcinoma cell line GRC-1].
    Xi Z; Yu L; Guo Y
    Zhonghua Yi Xue Za Zhi; 2000 Apr; 80(4):308-11. PubMed ID: 11798778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6 in renal cell carcinoma.
    Tsukamoto T; Kumamoto Y; Miyao N; Masumori N; Takahashi A; Yanase M
    J Urol; 1992 Dec; 148(6):1778-81; discussion 1781-2. PubMed ID: 1433606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synchronous presentation of breast carcinoma with plasmacytoid cytomorphology and multiple myeloma.
    Khalbuss WE; Fischer G; Ahmad M; Villas B
    Breast J; 2006; 12(2):165-7. PubMed ID: 16509843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of Fas/APO-1 in renal cell carcinoma GRC-1 cell line during cell cycles.
    Li H; Yu L; Guo Y; Liang Y; Wang D
    Chin Med J (Engl); 1999 Nov; 112(11):1008-12. PubMed ID: 11721461
    [No Abstract]   [Full Text] [Related]  

  • 27. Type 2 and clear cell papillary renal cell carcinoma, and tubulocystic carcinoma: a unifying concept.
    Brennan C; Srigley JR; Whelan C; Cooper J; Delahunt B
    Anticancer Res; 2010 Feb; 30(2):641-4. PubMed ID: 20332483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-interleukin-6 (IL-6) therapy of IL-6-producing renal cell carcinoma].
    Fujita J; Takenawa J; Kaneko Y; Okumura K; Yoshida O
    Hinyokika Kiyo; 1992 Nov; 38(11):1333-6. PubMed ID: 1485590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
    Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
    Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.
    Jourdan M; Zhang XG; Portier M; Boiron JM; Bataille R; Klein B
    J Immunol; 1991 Dec; 147(12):4402-7. PubMed ID: 1753108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression of TFAR19(PDCD5) in normal human kidney, renal clear cell carcinoma, normal human bladder and bladder carcinoma].
    Xiong L; Tan WL; Yu ZC; Wu YD; Huang H; Zhao GZ; Zhu WH; Zheng SB
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):805-9. PubMed ID: 16793605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma.
    Cozen W; Gebregziabher M; Conti DV; Van Den Berg DJ; Coetzee GA; Wang SS; Rothman N; Bernstein L; Hartge P; Morhbacher A; Coetzee SG; Salam MT; Wang W; Zadnick J; Ingles SA
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2285-91. PubMed ID: 17119059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues.
    Perego RA; Bianchi C; Corizzato M; Eroini B; Torsello B; Valsecchi C; Di Fonzo A; Cordani N; Favini P; Ferrero S; Pitto M; Sarto C; Magni F; Rocco F; Mocarelli P
    J Proteome Res; 2005; 4(5):1503-10. PubMed ID: 16212400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [E-cadherin expression and histopathological features in renal cell carcinomas].
    Jin TX; Kakehi Y; Moroi S; Yoshida O
    Hinyokika Kiyo; 1995 Sep; 41(9):653-7. PubMed ID: 7484527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of bone morphogenetic protein 2 in ossification of renal cell carcinoma.
    Yamasaki M; Nomura T; Mimata H; Nomura Y
    J Urol; 2004 Aug; 172(2):475-6. PubMed ID: 15247706
    [No Abstract]   [Full Text] [Related]  

  • 36. P-glycoprotein activity in renal clear cell carcinoma.
    Soto-Vega E; Arroyo C; Richaud-Patin Y; García-Carrasco M; Vázquez-Lavista LG; Llorente L
    Urol Oncol; 2009; 27(4):363-6. PubMed ID: 18440836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calponin h1 expression in renal tumor vessels: correlations with multiple pathological factors of renal cell carcinoma.
    Islam AH; Ehara T; Kato H; Hayama M; Kobayashi S; Igawa Y; Nishizawa O
    J Urol; 2004 Mar; 171(3):1319-23. PubMed ID: 14767341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of hypoxia inducible factor-1alpha and glucose transporter protein 1 in renal and bladder cancers and the clinical significance thereof].
    Zhou JT; Cai ZM; Li NC; Na YQ
    Zhonghua Yi Xue Za Zhi; 2006 Jul; 86(28):1970-4. PubMed ID: 17064593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma.
    Meierhofer D; Mayr JA; Foetschl U; Berger A; Fink K; Schmeller N; Hacker GW; Hauser-Kronberger C; Kofler B; Sperl W
    Carcinogenesis; 2004 Jun; 25(6):1005-10. PubMed ID: 14764459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple myeloma and renal cell carcinoma possible association.
    Badros A; Karakunnel J; Dawson N
    Leuk Lymphoma; 2007 Aug; 48(8):1662-4. PubMed ID: 17701606
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.